Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center

Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center

Introduction: Functioning neuroendocrine tumors (NETs) that do not respond to standard therapies are commonly considered for Peptide Receptor Radionuclide Therapy (PRRT). The benefit of 177Lu-DOTATATE PRRT in patients with progressive metastatic NET was analyzed and survival in multi-organ involveme...

Full description

Saved in:
Bibliographic Details
Main Authors: David Mathew, Saumya S. Sunny, Justin Benjamin, Junita R. John, Felix K. Jebasingh, Josh T. Georgy, Ashish Singh, Regi Oommen
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-12-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
68ga-dotatate
kaplan–meier survival estimates
177lu-dotatate
net
neuroendocrine tumor
peptide receptor radionuclide therapy
prrt
Online Access:https://journals.lww.com/10.4103/ijem.ijem_372_23
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.lww.com/10.4103/ijem.ijem_372_23

Similar Items